PITUITARY AND OVARIAN SUPPRESSION AFTER EARLY FOLLICULAR AND MID-LUTEAL ADMINISTRATION OF A LHRH AGONIST IN A DEPOT FORMULATION - DECAPEPTYL CR

被引：38

作者：

BROEKMANS, FJ

BERNARDUS, RE

BERKHOUT, G

SCHOEMAKER, J

机构：

[1] Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Vrije Universiteit, Amsterdam

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 03期

关键词：

LUTEINIZING HORMONE RELEASING HORMONE AGONIST; TRIPTORELIN; PITUITARY; DEPOT FORMULATION;

D O I：

10.3109/09513599209015549

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In order to study its effect on pituitary and ovarian function, a single dose of triptorelin depot (Decapeptyl CR(R), Ferring) was administered to 12 women in the early follicular (EF,n = 6) or mid-luteal phase (ML, n = 6) of a normal cycle. In all 12 women the initial pituitary and ovarian responses were similar. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) rose to peak values within 48 h, and declined to hypogonadotropic levels within 2 weeks' time. Steroid levels showed a slight to marked rise after injection and fell to hypogonadal values within 1 week. LH suppression was maintained until the 8th week after the injection, while FSH levels rose to normal between the 3rd and 4th week. Estrogen secretion started to be restored in the course of the 7th and 8th week. Menses occurred between the 11th and 13th week after the injection of the drug. This study demonstrates the possibility of rapid induction of a hypogonadotropic and hypogonadal condition in regularly cycling women by administration of a single triptorelin depot. Suppression of pituitary and ovarian function appears to be continued until the 8th week after the injection.

引用

页码：153 / 161

页数：9

共 47 条

[11]

Wennink J., Delemarre-van de Waal H., van Kessel H., Mulder G.H., Foster J.P., Schoemaker J., Luteinizing hormone secretion patterns in boys at the onset of puberty measured using a highly sensitive immunoradiometric assay, J. Clin. Endocrinol. Metab., 67, pp. 924-929, (1988)

[12]

Koziol J.A., Maxwell D.A., A distribution free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment, Biometrics, 37, pp. 383-390, (1981)

[13]

Bhasin S., Swerdloff R.S., Mechanisms of gonadotropin-releasing hormone agonist action in the human male, Endocr. Rev., 7, pp. 106-114, (1986)

[14]

Casper R.F., Erickson G.F., Yen S.S.C., Studies on the effect of gonadotropin-releasing hormone and its agonist on human luteal steroidogenesis in vitro, Fertil. Steril., 42, pp. 39-43, (1984)

[15]

Casper R.F., Erickson G.F., Rebar R.W., Yen S.S.C., The effect of luteinizing hormone-releasing hormone and its agonist on cultured human granulosa cells, Fertil. Steril., 37, pp. 406-409, (1982)

[16]

Parinaud J., Beaur A., Bourreau E., Vieitez G., Pontonnier G., Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells, Fertil. Steril., 50, pp. 597-602, (1988)

[17]

Tureck R.W., Mastroianni L., Blasco L., Strauss J.F., Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist, J. Clin. Endocrinol. Metab., 54, pp. 1078-1080, (1982)

[18]

Bramley T.A., Menzies G.S., Baird D.T., Specificity of gonadotropin-releasing hormone binding sites of the human corpus luteum: comparison with receptors of rat pituitary gland, J. Endocrinol., 108, pp. 323-328, (1986)

[19]

Evans R.M., Doelle G.C., Alexander A.N., Uderman H.D., Rabin D., Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men, J. Clin. Endocrinol. Metab., 58, pp. 862-867, (1984)

[20]

Lemay A., Maheux R., Faure N., Jean C., Fazekas A.T.A., Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis, Fertil. Steril., 41, pp. 863-871, (1984)

← 1 2 3 4 5 →